Cited by 284Advanced Glycation End Products researchRetinal Diseases and TreatmentsAldose Reductase and Taurine

Negative consequences of glycation

Brownlee, Michael·2000·Metabolism

Abstract

The Diabetes Control and Complications Trial (DCCT) established unequivocally that the effects of inadequate insulin action (as monitored by the level of hyperglycemia) are associated with the incidence and progression of diabetic retinopathy, nephropathy, and neuropathy. How does hyperglycemia induce the functional and morphologic changes that characterize diabetic complications? Increasing evidence points to a major role for sugar-derived advanced glycation end products (AGEs), which form inside and outside cells as a function of glucose concentration. Recent work in this area supports a central role for reactive oxygen species (ROS) in both the formation of AGEs, and in AGE-induced pathologic alterations in gene expression. Inhibition of ROS may also be centrally important in the action of drugs that prevent complications in diabetic animal models.

Integrity signals

Registry

Crossref · 10.1016/s0026-0495(00)80078-5

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Brownlee, M.
Affiliations
Albert Einstein College of Medicine (US)
Corresponding author
Brownlee, Michael
Venue
Metabolism
Publisher
Elsevier BV
Published
2000-02
Volume
49
Issue
2
Pages
9-13
ISSN
0026-0495 (ISSN-L)
OpenAlex
W2140945151
Cited by
284
References
77
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 10 · 2015: 8 · 2014: 11 · 2013: 15 · 2012: 16
FWCI
2.87
Type
journal article
Language
en
Open access
closed
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
Keywords
advanced glycation end products, hyperglycemia, diabetes complications, reactive oxygen species, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, insulin resistance, gene expression, AGE inhibitors, Diabetes Control and Complications Trial
MeSH terms
Receptor for Advanced Glycation End Products, Animals, Cell Communication, Extracellular Matrix, Glucose, Humans, Receptors, Immunologic, Gene Expression, Glycation End Products, Advanced

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review